The University of Osaka · Medicine
Professor Mitsuyoshi Takahara's research lab specializes in clinical and translational diabetes research, with a focus on insulin resistance, β-cell function, and metabolic complications in type 2 diabetes. The lab investigates the impact of glycemic control and novel antihyperglycemic agents—particularly SGLT2 inhibitors—on pancreatic β-cell recovery and long-term outcomes in diabetic patients. Using oral glucose tolerance tests and metabolic indices like the Matsuda Index, the lab aims to identify early markers of insulin resistance and optimize individualized diabetes management in the Japanese population. Their work bridges clinical observation with metabolic physiology to improve both survival and limb preservation in patients with diabetic complications such as critical limb ischemia.
Figures are computed from collected data and may differ slightly.
Diabetes with poor glycemic control is associated with major amputation, but not mortality, in CLI patients undergoing PTA. Prognostic indicators seem somewhat different between survival and limb salvage in the population.
It remains to be seen whether pancreatic β cell dysfunction in type 2 diabetic patients can be ameliorated just by correcting hyperglycemia. The current pilot study investigated β cell function after a four-week treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Ten participants (age, 51±13 years; hemoglobin A1c levels, 9.4±1.0%) took 50 mg of ipragliflozin L-proline for four weeks and thereafter discontinued the ag
We investigated the cut-off point of the Matsuda Index in Japanese according to the guideline from the Clinical and Laboratory Standards Institute. A total of 1,596 subjects free from medications for diabetes mellitus, dyslipidemia and/or hypertension, and without cardiovascular diseases or chronic renal failure underwent a health check-up and oral glucose tolerance test (OGTT). We recruited 204 healthy reference individuals with normal glucose tolerance without obesity, any component of metabol
Open papers in the app to read, cite, and organize with AI.
